Novo-Nordisk A/S News

Notable Healthcare Headlines for the Week: Novo Nordisk, Thermo Fisher and UnitedHealth in Focus

Seeking AlphaJun 15 09:05 ET

Eli Lilly's Early-stage Obesity Drug Causes up to 11% of Weight Loss in Three Months

Seeking AlphaJun 14 08:46 ET

Health Care Roundup: Market Talk

WSJJun 14 04:20 ET

Novo Nordisk Is Europe's Most Valuable Company -- Again. Eli Lilly, Watch Out

Barron'sJun 13 13:47 ET

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

BenzingaJun 13 10:46 ET

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

BenzingaJun 13 10:30 ET

Novo-Nordisk A/S (NVO.US) stock price rebounded, reclaiming the title of the highest Market Cap among European listed companies.

Novo-Nordisk A/S has surpassed SAP to become the most valuable publicly traded company in Europe.

Zhitong FinanceJun 13 08:03 ET

Multiple bullish factors drive Novo-Nordisk A/S to regain the top spot in Europe's market cap ranking.

① Novo-Nordisk announced on Thursday that it will advance the Phase III clinical trial of its new generation weight loss drug "Amycretin"; ② This week, media reported that the activist hedge fund Parvus Asset Management is increasing its shareholding in Novo-Nordisk.

cls.cnJun 13 07:41 ET

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

WSJJun 13 07:39 ET

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

WSJJun 13 06:04 ET

Multiple Bullish factors released, Goldman Sachs is Bullish on Novo-Nordisk A/S (NVO.US) with an increase of over 48%.

Goldman Sachs has rated Novo-Nordisk A/S Stocks as "Buy" with a 12-month Target Price of $117. This Target Price represents a potential upside of 48.6% compared to the stock's closing price on June 11.

Zhitong FinanceJun 13 04:54 ET

After Ousting CEO, Novo Nordisk Reclaims Crown as Largest European Company

MarketWatchJun 13 04:48 ET

Research Alert: CFRA Keeps Hold Opinion On Adss Of Novo Nordisk

MT NewswiresJun 13 04:35 ET · Ratings

The weight loss market is stirring again! Novo-Nordisk A/S's new drug will enter phase three clinical trials next year.

① Novo-Nordisk A/S announced that it will advance the Phase III clinical trial of the weight management drug "Amycretin," which is planned to start in the first quarter of 2026; ② According to early trial results published in January, participants receiving the highest dose of Amycretin through subcutaneous injection experienced a weight loss of 22.0% after 36 weeks.

cls.cnJun 12 18:49 ET

Novo-Nordisk A/S Options Spot-On: On June 12th, 68,152 Contracts Were Traded, With 560.38K Open Interest

Moomoo NewsJun 12 16:30 ET

Unusual Options Activity: BDX, SN and Others Attract Market Bets, BDX V/OI Ratio Reaches 753.8

Moomoo NewsJun 12 16:30 ET

Sector Update: Health Care Stocks Higher Late Afternoon

MT NewswiresJun 12 16:03 ET

Sector Update: Health Care

MT NewswiresJun 12 15:27 ET

Novo Nordisk Plans Late-stage Trials for Weight-loss Drug Amycretin

InvestingJun 12 14:26 ET

Novo Nordisk to Launch Late-stage Program to Test Novel Obesity Candidate

Seeking AlphaJun 12 14:14 ET